Literature DB >> 19116092

Surgical options in the management of ureteropelvic junction obstruction.

Douglas E Sutherland, Thomas W Jarrett.   

Abstract

Ureteropelvic junction obstruction (UPJO) is a common cause of upper urinary tract obstruction that can be clinically silent or lead to symptoms such as pain, chronic urinary tract infections, and urinary stone disease. UPJO does not always mandate treatment, but when an indication for correction is present, there are several minimally invasive surgical options available. Surgical reconstruction represents the gold-standard treatment for UPJO, although endoscopic pyelotomy is a well established and efficacious alternative.

Entities:  

Mesh:

Year:  2009        PMID: 19116092     DOI: 10.1007/s11934-009-0006-y

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  35 in total

1.  Percutaneous endopyelotomy.

Authors:  N O Bernardo; A D Smith
Journal:  Urology       Date:  2000-08-01       Impact factor: 2.649

2.  Long-term results of percutaneous endopyelotomy in the treatment of children with failed open pyeloplasty.

Authors:  G Capolicchio; Y L Homsy; A M Houle; A Brzezinski; L Stein; M M Elhilali
Journal:  J Urol       Date:  1997-10       Impact factor: 7.450

3.  Endopyelotomy for primary ureteropelvic junction obstruction: risk factors determine the success rate.

Authors:  H Danuser; D K Ackermann; D Böhlen; U E Studer
Journal:  J Urol       Date:  1998-01       Impact factor: 7.450

4.  Salvage laparoscopic pyeloplasty in the worst case scenario: after both failed open repair and endoscopic salvage.

Authors:  Brian M Levin; S Duke Herrell
Journal:  J Endourol       Date:  2006-10       Impact factor: 2.942

5.  Laparoscopic pyeloplasty with concomitant pyelolithotomy.

Authors:  Sanjay Ramakumar; Vanessa Lancini; David Y Chan; J Kellogg Parsons; Louis R Kavoussi; Thomas W Jarrett
Journal:  J Urol       Date:  2002-03       Impact factor: 7.450

6.  Comparison of open versus laparoscopic pyeloplasty techniques in treatment of uretero-pelvic junction obstruction.

Authors:  H Christoph Klingler; Mesut Remzi; Guenter Janetschek; Christian Kratzik; Michael J Marberger
Journal:  Eur Urol       Date:  2003-09       Impact factor: 20.096

7.  [History of ureteropelvic junction obstruction repair (pyeloplasty). From Trendelenburg (1886) to the present].

Authors:  V Poulakis; U Witzsch; D Schultheiss; P Rathert; E Becht
Journal:  Urologe A       Date:  2004-12       Impact factor: 0.639

8.  Ileal ureteric replacement in complex reconstruction of the urinary tract.

Authors:  R Bonfig; E W Gerharz; H Riedmiller
Journal:  BJU Int       Date:  2004-03       Impact factor: 5.588

9.  Laparoscopic pyeloplasty for secondary ureteropelvic junction obstruction.

Authors:  Chandru P Sundaram; Robert L Grubb; Jamil Rehman; Yan Yan; Cathy Chen; Jaime Landman; Elspeth M McDougall; Ralph V Clayman
Journal:  J Urol       Date:  2003-06       Impact factor: 7.450

10.  Pediatric laparoscopic pyeloplasty: 4-year experience.

Authors:  Po N Lam; Carson Wong; Timothy L Mulholland; Jeffery B Campbell; Bradley P Kropp
Journal:  J Endourol       Date:  2007-12       Impact factor: 2.942

View more
  3 in total

1.  Renal function recovery after laparosocopic pyeloplasty.

Authors:  Juan Gómez Rivas; Sergio Alonso Y Gregorio; María Portilla Eastmond; Angel Tabernero Gómez; Luis Hidalgo Togores; Jesús Díez Sebastián; Jesús Javier de la Peña Barthel
Journal:  Cent European J Urol       Date:  2014-06-23

2.  Comparison of Retrograde Balloon Dilatation and Laparoscopic Pyeloplasty for Treatment of Ureteropelvic Junction Obstruction: Results of a 2-Year Follow-Up.

Authors:  Ning Xu; Shao-Hao Chen; Xue-Yi Xue; Qing-Shui Zheng; Yong Wei; Tao Jiang; Xiao-Dong Li; Jin-Bei Huang; Hai Cai
Journal:  PLoS One       Date:  2016-03-28       Impact factor: 3.240

3.  Evaluation of Caspase 3 Enzyme and TNF-alpha as Biomarkers in Ureteropelvic Junction Obstruction in Children- a preliminary report.

Authors:  Mehdi Shirazi; Ali Eslahi; Vahidreza Sharifi; Fatemeh Rahimi; Alireza Safarpour
Journal:  Pak J Med Sci       Date:  2017 Mar-Apr       Impact factor: 1.088

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.